Blockbusters continue to dominate sales notes URCH Publishing.
LONDON--(BUSINESS WIRE)-- Over one third of the $808 billion pharmaceutical market is generated by just 100 drugs, says a new report from URCH Publishing, a leading provider of pharmaceutical industry business information.
The report, Pharmaceutical Market Trends, 2010 - 2014 - Key market forecasts and growth opportunities, which is published today, notes that 125 drugs generate over $1 billion a year in global sales and the top 100 have accumulated sales of $258 billion, accounting for 35.3% of the total pharmaceutical market.
The top 20 pharmaceutical products all generated sales in excess of US$4 billion and accounted for 14.6% of the total pharmaceutical market.
There were a total of seven new blockbuster drugs in 2009, generating combined sales of US$9.8 billion.
However, only three of the top 10 products in 2009 are forecast to increase sales over the next five years as generics bite into their market share. Pfizer/Astellas’ Lipitor, Sanofi-Aventis/BMS’s Plavix, Novartis’ Diovan/Co-Diovan and AstraZeneca’s Seroquel will all lose patent protection in the US by the end of 2012 and suffer a significant loss of sales as a result.
Pfizer had the most blockbuster products with 14 (including five inherited through the acquisition of Wyeth). Pfizer also achieved the greatest share of blockbuster sales with 11.7%.
The global pharmaceutical market is forecast to grow to US$1,033 billion in 2014, an equivalent CAGR of 5.0% over the next five years. The 142 page study says future sales growth will remain limited by cost-containment measures in Europe and high prescription drug co-pays for insured consumers in the US. The contribution to future growth from developing European markets will begin to slow as healthcare funding in those markets begins to reach a plateau, while centralised regulation will limit the pricing for innovative drugs in Europe relative to prices in the US.
“Pharmaceutical Market Trends, 2010 - 2014 - Key market forecasts and growth opportunities (4rd Edition)” is available from URCH Publishing. Find more details at:
About URCH Publishing Ltd (http://www.urchpublishing.com)
URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry.
+44 (0)207 060 1099
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Pharmaceutical Communications Publishing Medical Supplies